Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Bicycle Therapeutics
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
December 14, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Host R&D Day on December 14
November 30, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
October 19, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
September 11, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
February 14, 2023
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 10, 2022
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2022
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Tickers
BCYC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.